title: The bacterial protein azurin impairs invasion and FAK/Src signaling in P-cadherin-overexpressing breast cancer cell models.
abstract: P-cadherin overexpression occurs in about 30% of all breast carcinomas, being a poor prognostic factor for breast cancer patients. In a cellular background of wild-type E-cadherin, we have previously shown that its expression promotes invasion, motility and migration of breast cancer cells due to the induced secretion of metalloproteases (MMPs) to the extracellular medium and to the concomitant shedding of a pro-invasive soluble form of this protein (sP-cad). Azurin is secreted by Pseudomonas aeruginosa and induces in vitro and in vivo cytotoxicity after its preferential penetration in human cancer cells relative to normal cells. Three different breast cancer cell lines, MCF-7/AZ.Mock, MCF-7/AZ.Pcad and SUM149 were treated with sub-killing doses of azurin. Invasion of these cells was measured using Matrigel Invasion Assays and MTT assays were performed to determine cell viability upon treatment and the effects on cadherins expression was determined by Western blot and Immunofluorescence. Gelatin Zymography was used to determine activity of MMP2 in the conditioned media of azurin treated and untreated cells and the phosphorylation levels of intracellular signaling proteins were determined by Western blot. The invasive phenotype of these breast cancer cells was significantly reduced by azurin. Azurin (50-100 µM) also caused a specific decrease on P-cadherin protein levels from 30-50% in MCF-7/AZ.Pcad and SUM149 breast cancer cell lines, but the levels of E-cadherin remain unaltered. More, the levels of sP-cad and the activity of MMP2 were reduced in the extracellular media of azurin treated cells and we also observed a decrease in the phosphorylation levels of both FAK and Src proteins. Our data show that azurin specifically targets P-cadherin, not E-cadherin, abrogating P-cadherin-mediated invasive effects and signaling. Therefore, azurin could possibly be considered a therapeutic tool to treat poor-prognosis breast carcinomas overexpressing P-cadherin in a wild type E-cadherin context.
authors.affiliation: Institute for Biotechnology and Bioengineering, Center for Biological and Chemical Engineering, Instituto Superior Técnico, Lisbon, Portugal.
authors.forename: Nuno
authors.initials: N
authors.lastname: Bernardes
authors.forename: Ana Sofia
authors.initials: AS
authors.lastname: Ribeiro
authors.forename: Sofia
authors.initials: S
authors.lastname: Abreu
authors.forename: Bruna
authors.initials: B
authors.lastname: Mota
authors.forename: Rute G
authors.initials: RG
authors.lastname: Matos
authors.forename: Cecilia M
authors.initials: CM
authors.lastname: Arraiano
authors.forename: Raquel
authors.initials: R
authors.lastname: Seruca
authors.forename: Joana
authors.initials: J
authors.lastname: Paredes
authors.forename: Arsenio M
authors.initials: AM
authors.lastname: Fialho
mesh_terms: D001400:Azurin / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000494:pharmacology; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D015820:Cadherins / Q000235:genetics* / Q000378:metabolism; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D051417:Focal Adhesion Kinase 1 / Q000378:metabolism*; D015870:Gene Expression; D006801:Humans; D061986:MCF-7 Cells; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D019061:src-Family Kinases / Q000378:metabolism*
chemical_list: D001426:Bacterial Proteins; D015820:Cadherins; D001400:Azurin; D051417:Focal Adhesion Kinase 1; D019061:src-Family Kinases; D020778:Matrix Metalloproteinase 2
references.citation: Cell Mol Life Sci. 2011 Dec;68(23):3853-68
references.pmid: 21744247
references.citation: Oncogene. 2004 Mar 25;23(13):2367-78
references.pmid: 14981543
references.citation: Cancer Res. 2009 Jan 15;69(2):537-46
references.pmid: 19147567
references.citation: Cell. 2010 Apr 2;141(1):52-67
references.pmid: 20371345
references.citation: Clin Exp Metastasis. 2007;24(8):685-97
references.pmid: 17952616
references.citation: Microbiology (Reading). 2000 Oct;146 ( Pt 10):2521-2530
references.pmid: 11021927
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14098-103
references.pmid: 12393814
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):5869-77
references.pmid: 16115928
references.citation: Biochemistry. 2007 Feb 20;46(7):1799-810
references.pmid: 17249693
references.citation: J Pathol. 2013 Apr;229(5):705-18
references.pmid: 23180380
references.citation: Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4770-5
references.pmid: 15044691
references.citation: Cell Microbiol. 2005 Oct;7(10):1418-31
references.pmid: 16153242
references.citation: Int J Dev Biol. 2011;55(7-9):811-22
references.pmid: 22161837
references.citation: J Biol Chem. 2006 Dec 8;281(49):37728-37
references.pmid: 17035230
references.citation: Cancer Metastasis Rev. 2009 Jun;28(1-2):35-49
references.pmid: 19169797
references.citation: Cancer Res. 2005 Oct 1;65(19):8774-83
references.pmid: 16204047
references.citation: J Cell Physiol. 2010 Apr;223(1):14-26
references.pmid: 20049846
references.citation: Cancer Sci. 2008 Nov;99(11):2160-9
references.pmid: 18811693
references.citation: Oncogene. 2010 Jan 21;29(3):392-402
references.pmid: 19901964
references.citation: Br J Cancer. 1991 Jun;63(6):867-72
references.pmid: 1648947
references.citation: Cancer Res. 1998 Mar 1;58(5):900-3
references.pmid: 9500447
references.citation: J Cell Sci. 2001 Jan;114(Pt 1):111-118
references.pmid: 11112695
references.citation: J Cell Biol. 2003 Mar 3;160(5):753-67
references.pmid: 12615911
references.citation: Cancer Lett. 2010 Mar 28;289(2):127-39
references.pmid: 19643531
references.citation: Angiogenesis. 2011 Sep;14(3):355-69
references.pmid: 21667138
references.citation: Cancer Res. 2004 Nov 15;64(22):8309-17
references.pmid: 15548699
references.citation: Biochim Biophys Acta. 2012 Dec;1826(2):297-311
references.pmid: 22613680
references.citation: Mol Cancer Ther. 2009 Oct;8(10):2947-58
references.pmid: 19808975
references.citation: Clin Cancer Res. 2010 Nov 1;16(21):5177-88
references.pmid: 20829331
references.citation: Biochem Biophys Res Commun. 2005 Jul 15;332(4):965-8
references.pmid: 15913547